4.3 Article

A Multifunctional Nanocrystalline CaF2: Tm, Yb@mSiO2 System for Dual-Triggered and Optically Monitored Doxorubicin Delivery

期刊

PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION
卷 33, 期 12, 页码 896-905

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/ppsc.201600166

关键词

-

资金

  1. National Nature Science Foundation of China [51232006, 51672247]
  2. Natural Science Foundation of Zhejiang Province [LY15E020005, LZ16E030001]
  3. National Institutes of Health [CA200504]

向作者/读者索取更多资源

Daunting challenges in investigating the controlled release of drugs in complicated intracellular microenvironments demand the development of stimuliresponsive drug delivery systems. Here, a nanoparticle system, CaF2:Tm,Yb@mSiO(2), made of a mesoporous silica (mSiO(2)) nanosphere with CaF2:Tm,Yb upconversion nanoparticles (UCNPs) is developed, filling its mesopores and with its surface-modified with polyacrylic acid for binding the anticancer drug molecules (doxorubicin, DOX). The unique design of CaF2: Tm, Yb@ mSiO(2) enables us to trigger the drug release by two mechanisms. One is the pH-triggered mechanism, where drug molecules are preferentially released from the nanoparticles at acidic conditions unique for the intracellular environment of cancer cells compared to normal cells. Another is the 808 nm near infrared (NIR)-triggered mechanism, where 808 nm NIR induces the heating of the nanoparticles to weaken the electrostatic interaction between drug molecules and nanoparticles. In addition, luminescence resonance energy transfer occurs from the UCNPs (the energy donor) to the DOX drug (the energy acceptor) in the presence of 980 nm NIR irradiation, allowing us to monitor the drug release by detecting the vanishing blue emission from the UCNPs. This study demonstrates a new multifunctional nanosystem for dual-triggered and optically monitored drug delivery, which will facilitate the rational design of personalized cancer therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据